Exciting news has recently emerged from the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration: the clinical trial for KSD-101 Injection, developed by Hensen Bio, has been approved. The indicated use is for “EBV-associated hematological tumors that have not responded to standard treatment.”
This revolutionary treatment is now being made available to eligible patients worldwide through the **Beijing South Region Oncology Hospital International Department**. We are dedicated to translating cutting-edge scientific research into clinical practice, offering international patients top-tier medical services and a new therapeutic option.
KSD-101 is an autologous dendritic cell vaccine, derived from human monocytes and loaded with EBV-associated tumor antigen complexes. The latest findings from its Phase I clinical trial were presented at the 2025 Annual Meeting of the European Hematology Association (EHA), showcasing its significant potential in the field of immunotherapy.
The Phase I clinical study enrolled patients with various types of Epstein-Barr virus-associated lymphoproliferative diseases (EBV-LPDs), including several refractory conditions such as Angioimmunoblastic T-cell Lymphoma (AITL), Nasal-type/Peripheral NK/T-cell Lymphoma (ENKTL), Chronic Active Epstein-Barr Virus infection (CAEBV), EBV-associated Hemophagocytic Lymphohistiocytosis (HLH), Diffuse Large B-cell Lymphoma (DLBCL), and Hodgkin Lymphoma (HL).
Study results showed that at a median follow-up of 42.7 weeks, treatment with KSD-101 led to positive disease remission, with the majority of patients achieving and maintaining Complete Remission (CR). These data offer new hope for patients who have failed standard therapies.
In terms of safety, treatment-related Adverse Events (AEs) were primarily mild reactions, such as injection site reactions, fever, and lymphadenopathy. No Grade ≥3 toxicity was observed, indicating a favorable tolerability profile. This suggests that KSD-101 is not only effective but also relatively safe, supporting its potential for long-term treatment.
**Why Choose Beijing South Region Oncology Hospital International Department?**
As a trusted medical destination for international patients, we provide comprehensive, multilingual international medical services. From initial assessment and treatment plan customization to subsequent follow-up, our expert team is committed to delivering personalized and precise medical care for every international patient.
Do not let geographical boundaries limit your access to the best possible treatment. If you or your family member is suffering from EBV-associated hematological tumors and has not responded to standard treatment, please contact us immediately.
**Contact Us Now for a Treatment Plan Evaluation**
Our International Department team is ready to assist you. You can reach us through any of the following methods to begin your journey towards advanced treatment:
- ��� Phone Consultation: 400-880-3716
- ��� WeChat Consultation: 17801183037
- ��� Email:
- 100085_010@163.com
- myimmnet@163.com
**Beijing South Region Oncology Hospital International Department**
Your International Window for Cancer Treatment
Post time: Mar-12-2026